Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma: Research paper

Shirshendu Sinha, S Vincent Rajkumar, Martha Lacy, Suzanne R. Hayman, Francis K. Buadi, Angela Dispenzieri, David M Dingli, Robert A. Kyle, Morie Gertz, Shaji K Kumar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term outcome. We studied a cohort of 182 patients with newly diagnosed myeloma seen between March 1998 and June 2007, initially treated with single-agent Dex for at least 4 weeks. The median age at diagnosis was 63 years (range, 39-81) and the median estimated survival was 55 months. At a median duration of therapy of 15 weeks, 91 (50%) patients had a partial response or better, 80 (44%) had less than partial response and the remaining (6%) patients were not evaluable. The median overall survival from diagnosis for the responders was 75 months compared to 71 months for remaining patients, P = 0·6.There was no correlation between baseline disease characteristics and Dex responsiveness. While overall survival was longer for the 130 (70%) patients who proceeded to an autologous stem cell transplant, no correlation was found between survival and Dex responsiveness among either group. Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome.

Original languageEnglish (US)
Pages (from-to)853-858
Number of pages6
JournalBritish Journal of Haematology
Volume148
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Multiple Myeloma
Dexamethasone
Research
Survival
Steroids
Stem Cells
Transplants
Therapeutics

Keywords

  • Dexamethasone
  • Multiple Myeloma
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

@article{bec9d0b6d6c242c59b815b6b61a694a8,
title = "Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma: Research paper",
abstract = "Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60{\%}. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term outcome. We studied a cohort of 182 patients with newly diagnosed myeloma seen between March 1998 and June 2007, initially treated with single-agent Dex for at least 4 weeks. The median age at diagnosis was 63 years (range, 39-81) and the median estimated survival was 55 months. At a median duration of therapy of 15 weeks, 91 (50{\%}) patients had a partial response or better, 80 (44{\%}) had less than partial response and the remaining (6{\%}) patients were not evaluable. The median overall survival from diagnosis for the responders was 75 months compared to 71 months for remaining patients, P = 0·6.There was no correlation between baseline disease characteristics and Dex responsiveness. While overall survival was longer for the 130 (70{\%}) patients who proceeded to an autologous stem cell transplant, no correlation was found between survival and Dex responsiveness among either group. Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome.",
keywords = "Dexamethasone, Multiple Myeloma, Survival",
author = "Shirshendu Sinha and Rajkumar, {S Vincent} and Martha Lacy and Hayman, {Suzanne R.} and Buadi, {Francis K.} and Angela Dispenzieri and Dingli, {David M} and Kyle, {Robert A.} and Morie Gertz and Kumar, {Shaji K}",
year = "2010",
doi = "10.1111/j.1365-2141.2009.08023.x",
language = "English (US)",
volume = "148",
pages = "853--858",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma

T2 - Research paper

AU - Sinha, Shirshendu

AU - Rajkumar, S Vincent

AU - Lacy, Martha

AU - Hayman, Suzanne R.

AU - Buadi, Francis K.

AU - Dispenzieri, Angela

AU - Dingli, David M

AU - Kyle, Robert A.

AU - Gertz, Morie

AU - Kumar, Shaji K

PY - 2010

Y1 - 2010

N2 - Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term outcome. We studied a cohort of 182 patients with newly diagnosed myeloma seen between March 1998 and June 2007, initially treated with single-agent Dex for at least 4 weeks. The median age at diagnosis was 63 years (range, 39-81) and the median estimated survival was 55 months. At a median duration of therapy of 15 weeks, 91 (50%) patients had a partial response or better, 80 (44%) had less than partial response and the remaining (6%) patients were not evaluable. The median overall survival from diagnosis for the responders was 75 months compared to 71 months for remaining patients, P = 0·6.There was no correlation between baseline disease characteristics and Dex responsiveness. While overall survival was longer for the 130 (70%) patients who proceeded to an autologous stem cell transplant, no correlation was found between survival and Dex responsiveness among either group. Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome.

AB - Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates of 50-60%. It is unclear whether steroid responsiveness reflects any biological characteristic that impacts long-term outcome. We studied a cohort of 182 patients with newly diagnosed myeloma seen between March 1998 and June 2007, initially treated with single-agent Dex for at least 4 weeks. The median age at diagnosis was 63 years (range, 39-81) and the median estimated survival was 55 months. At a median duration of therapy of 15 weeks, 91 (50%) patients had a partial response or better, 80 (44%) had less than partial response and the remaining (6%) patients were not evaluable. The median overall survival from diagnosis for the responders was 75 months compared to 71 months for remaining patients, P = 0·6.There was no correlation between baseline disease characteristics and Dex responsiveness. While overall survival was longer for the 130 (70%) patients who proceeded to an autologous stem cell transplant, no correlation was found between survival and Dex responsiveness among either group. Among this cohort of patients with myeloma, failure to respond to single agent steroid did not have an adverse impact on eventual outcome.

KW - Dexamethasone

KW - Multiple Myeloma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77649227672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649227672&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.08023.x

DO - 10.1111/j.1365-2141.2009.08023.x

M3 - Article

C2 - 19958361

AN - SCOPUS:77649227672

VL - 148

SP - 853

EP - 858

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -